The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Richey William Drake | Director | Grant(A) | 25K | — | $0 |
| Jun 4, 2026 | Yee John D. | Director | Grant(A) | 25K | — | $0 |
| Mar 24, 2026 | Angel Matthew | CEO and President, Director, 10% Owner | Buy(P) | 231K | $2.16 | $500K |
| Feb 4, 2026 | Angel Matthew | CEO and President, Director, 10% Owner | Grant(A) | 270K | — | $0 |
| Jan 27, 2026 | Pellizzari Christine A | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Nichol Geoffrey | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Raab Michael | Director | Grant(A) | 1K | — | $0 |
| Jan 27, 2026 | Simantov Ronit | Director | Grant(A) | 1K | — | $0 |
| Jan 2, 2025 | Maestas Nicholas | Chief Financial Officer | Grant(A) | 200K | — | $0 |
| Jan 2, 2025 | Whiting Samuel | Chief Medical Officer | Grant(A) | 270K | — | $0 |
| Jan 2, 2025 | Brady Stephen R | President and CEO, Director | Grant(A) | 550K | — | $0 |
| Jan 2, 2025 | Trojanowski Justin | Corporate Controller | Grant(A) | 30K | — | $0 |
| Aug 12, 2024 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 388K | $1.10 | $427K |
| Aug 8, 2024 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 400K | $1.35 | $540K |
| Jul 3, 2024 | Brady Stephen R | President and CEO, Director | Buy(P) | 35K | $2.11 | $74K |
| Jul 2, 2024 | Whiting Samuel | Chief Medical Officer | Buy(P) | 5K | $2.13 | $10K |
| Jun 28, 2024 | Trojanowski Justin | Corporate Controller | Buy(P) | 8K | $2.16 | $16K |
| Jun 13, 2024 | Raab Michael | Director | Grant(A) | 16K | — | $0 |
| Jun 13, 2024 | Simantov Ronit | Director | Grant(A) | 16K | — | $0 |
| Jun 13, 2024 | Nichol Geoffrey | Director | Grant(A) | 16K | — | $0 |
| Jun 13, 2024 | Pellizzari Christine A | Director | Grant(A) | 16K | — | $0 |
| Jan 3, 2024 | Maestas Nicholas | VP of Strategy and Finance | Grant(A) | 40K | — | $0 |
| Jan 3, 2024 | Trojanowski Justin | Principal Accounting Officer | Grant(A) | 27K | — | $0 |
| Jan 3, 2024 | Whiting Samuel | Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Jan 3, 2024 | Brady Stephen R | President and CEO, Director | Grant(A) | 250K | — | $0 |
| Oct 11, 2023 | Maestas Nicholas | VP of Strategy and Finance | Grant(A) | 100K | — | $0 |
| Oct 11, 2023 | Whiting Samuel | Chief Medical Officer | Grant(A) | 325K | — | $0 |
| Oct 11, 2023 | Trojanowski Justin | Corporate Controller | Grant(A) | 55K | — | $0 |
| Oct 11, 2023 | Brady Stephen R | President and CEO, Director | Grant(A) | 725K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).